>it is my understanding this [phase-2 DIC] study is a dosing range study, and is not set up for efficacy results. What could we learn from the P2 study that will be of interest to the investment community?<
It’s a typical phase-2 study. It will measure efficacy but is not powered to detect a statsig difference in survival. The main thing to be learned is whether the drug works well enough to advance the DIC program to phase-3.
"...it is my understanding this study is a dosing range study, and is not set up for efficacy results."
I would like to know what you mean. Before you study the useful does range you need to establish efficacy. You can do them both at the same time.
GTC with partner Leo are looking forward to being proven effective in DIC sepsis cases. This would be a life saving 1-2 billion dollar drug, well in some people’s estimation.
GTC also has a deal with Merrimack who is in trials with a malaria drug. In that case Merrimack would create the drug and pay royalties to GTC for the process. If it works out, I don't know what thats worth.
In any case, we are looking two years down the pike. No quick buck here as ATryn, even with off-label use, can't bring GTC to profitability without additional approvals.
Market Data 
Markets 
AI
